HERV-K (HML-2) was shown to have markedly different titers in the blood of patients with lymphoma (e.g., HIV infection with diffuse large B-cell lymphoma (DLBCL), non-HIV diffuse large B-cell lymphoma, and HIV infection with Hodgkin lymphoma (HL)) compared to healthy individuals [95]. This evidence concerns the gene CLEC10A and lymphoma.